Focosi Daniele, Tuccori Marco, Franchini Massimo
North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
Division of Pharmacology and Pharmacovigilance, University of Pisa, 56126 Pisa, Italy.
Life (Basel). 2021 Feb 15;11(2):144. doi: 10.3390/life11020144.
Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emergency use authorization, have suggested benefit in early disease course (less than 72 hours from symptoms and seronegative). Meanwhile, polyclonal immunoglobulins (i.e., hyperimmune serum), derived either from CCP donations or from animals immunized with SARS-CoV-2 antigens, are likely to become the next nAb-derived candidate. We here discuss the pros and cons of hyperimmune serum versus CCP and mAb, and summarize the ongoing clinical trials of COVID-19 hyperimmune sera.
目前仍缺乏针对新冠病毒病（COVID-19）的特效治疗方法。在基于中和抗体（nAbs）的被动免疫疗法中，已获得紧急使用授权的COVID-19康复期血浆（CCP）抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白单克隆抗体（mAb）的随机对照试验表明，其对疾病早期病程（症状出现后72小时内且血清学阴性）有益。同时，源自CCP捐献或用SARS-CoV-2抗原免疫动物获得的多克隆免疫球蛋白（即超免疫血清），很可能成为下一个基于nAb的候选药物。我们在此讨论超免疫血清与CCP和mAb相比的优缺点，并总结正在进行的COVID-19超免疫血清临床试验。
